News & Press: Patient Safety

Premier Pharmacy Labs Issues Recall of Unexpired Sterile Drug Product Lots

Wednesday, June 19, 2019  

SIS Patient Safety Alert 06/19/2019: Premier Pharmacy Labs Issues Voluntary Nationwide Recall of All Unexpired Sterile Drug Product Lots Due to Lack of Sterility Assurance

This is an important alert from the Spine Intervention Society. SIS sends Patient Safety Alerts when it receives important information regarding products or services that can impact your patients' safety. When the Food and Drug Administration (FDA) issues a safety alert, or a company announces a recall or market withdrawal, the FDA posts the announcement as a public service. In such cases neither SIS nor the FDA endorse either the product or the company.

Premier Pharmacy Labs is voluntarily recalling all unexpired products, intended to be sterile, due to a lack of sterility assurance. The unexpired sterile drug product lots (include dates dispensed) are being recalled due to concerns presented during the latest FDA inspection including insufficient environmental controls, potential cross contamination and lack of product specific process validations. The nationwide recall includes lots of sterile drug products to the consumer/user level.

Administration of a drug product intended to be sterile that is not sterile could result in serious infections that may be life-threatening. To date, Premier Pharmacy Labs has not received any reports of adverse events related to the products but is issuing this recall out of an abundance of caution following a commitment made during a recent inspection of the company’s facility.

The scope of this recall is all commercially distributed product lots compounded in Premier Pharmacy Labs' Weeki Wachee, Florida location currently within their labeled expiration date in response to an FDA concerns raised during the most recent inspection carried out from April 29, 2019 to June 12, 2019.

Premier Pharmacy Labs is notifying customers of the voluntary recall by certified letter. Customers that have any of the affected medications that are being recalled should immediately quarantine the product, discontinue use and destroy per the hospital protocol.

Customers with any of the affected medications can also reference the Premier Pharmacy Labs website for more information on the specific lot numbers affected and contact information or click here for photos of the recalled products within the company announcement shared by the FDA.

Patients and healthcare providers with questions regarding this recall can contact Premier Pharmacy Labs at 1-800-752-7139, Monday through Friday, between 8:30am and 5pm, Central Standard Time or via e-mail at recalls@premierpharmacylabs.com.

Patients should contact their physician or healthcare provider if they have experienced any problems that may be related to the use of these products.

Adverse reactions or quality problems experienced with the use of these products may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.
  • Complete and submit the report online.
  • Regular Mail or Fax: Download the form or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178.


Source: Food and Drug Administration - Accessed 06/19/2019


Contact Us

120 E. Ogden Ave. Ste. 202
Hinsdale, Illinois 60521
P: 630.203.2252
Toll Free: 888.255.0005

© Copyright 2019 Spine Intervention Society 501(c)( 3) Privacy Policy  ::  Legal